Risk of SARS-CoV-2 Reinfection 3 Years after the Start of the Pandemic: A Population-Level Observational Study.
COVID-19
SARS-CoV-2
case fatality rate
reinfection
vaccination
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
24 Oct 2023
24 Oct 2023
Historique:
received:
13
09
2023
revised:
21
10
2023
accepted:
23
10
2023
medline:
25
11
2023
pubmed:
25
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
The risk of SARS-CoV-2 reinfections changes as new variants emerge, but the follow-up time for most of the available evidence is shorter than two years. This study evaluated SARS-CoV-2 reinfection rates in the total population of an Italian province up to three years since the pandemic's start. This retrospective cohort study used official National Healthcare System data on SARS-CoV-2 testing and vaccinations, demographics, and hospitalizations in the Province of Pescara, Italy, from 2 March 2020 to 31 December 2022. A total of 6541 (5.4%) reinfections and 33 severe and 18 lethal COVID-19 cases were recorded among the 121,412 subjects who recovered from a primary infection. There were no severe events following reinfection in the young population, whereas 1.1% of reinfected elderly died. A significantly higher reinfection risk was observed among females; unvaccinated individuals; adults (30-59 y); and subjects with hypertension, COPD, and kidney disease. Up to three years after a primary SARS-CoV-2 infection, the majority of the population did not experience a reinfection. The risk of severe COVID-19 following a reinfection was very low for young and adult individuals but still high for the elderly. The subjects with hybrid immunity showed a lower reinfection risk than the unvaccinated.
Identifiants
pubmed: 38004251
pii: life13112111
doi: 10.3390/life13112111
pmc: PMC10672528
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
BMC Public Health. 2023 Apr 28;23(1):778
pubmed: 37118717
Int J Infect Dis. 2023 Feb;127:63-68
pubmed: 36436752
J Infect. 2022 Aug;85(2):174-211
pubmed: 35472367
Front Med (Lausanne). 2022 Nov 09;9:1023507
pubmed: 36438045
Vaccines (Basel). 2023 Aug 04;11(8):
pubmed: 37631893
ERJ Open Res. 2023 Aug 21;9(4):
pubmed: 37362882
Int J Environ Res Public Health. 2023 Feb 14;20(4):
pubmed: 36834029
Int J Infect Dis. 2022 Oct;123:9-16
pubmed: 35931371
Lancet Reg Health Eur. 2022 Sep;20:100453
pubmed: 35791336
BMC Infect Dis. 2023 Jun 26;23(1):432
pubmed: 37365490
J Infect. 2022 Apr;84(4):542-550
pubmed: 35085659
Front Public Health. 2023 Jul 10;11:1191377
pubmed: 37492136
Int J Infect Dis. 2023 Jul;132:72-79
pubmed: 37072052
J Infect Public Health. 2023 Aug;16(8):1137-1141
pubmed: 37267680
Lancet Microbe. 2021 Dec;2(12):e666-e675
pubmed: 34632431
JAMA Intern Med. 2021 Oct 1;181(10):1407-1408
pubmed: 34048531
Front Public Health. 2022 May 02;10:884121
pubmed: 35586006
MMWR Morb Mortal Wkly Rep. 2023 Jun 23;72(25):683-689
pubmed: 37347715
J Public Health (Oxf). 2022 Dec 1;44(4):e475-e478
pubmed: 34492110
Lancet Infect Dis. 2023 May;23(5):556-567
pubmed: 36681084
Lancet Infect Dis. 2022 Nov;22(11):1535-1537
pubmed: 36179744
J Epidemiol Glob Health. 2023 Sep;13(3):577-588
pubmed: 37480426
J Clin Med. 2021 Dec 23;11(1):
pubmed: 35011781
Nature. 2022 Aug;608(7923):593-602
pubmed: 35714668
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Vaccines (Basel). 2023 Jun 30;11(7):
pubmed: 37515002
Eur J Epidemiol. 2022 Mar;37(3):235-249
pubmed: 35306604
Vaccines (Basel). 2022 Nov 08;10(11):
pubmed: 36366393
Nat Ecol Evol. 2023 Sep;7(9):1457-1466
pubmed: 37443189
Eur J Clin Invest. 2022 Oct;52(10):e13845
pubmed: 35904405
Lancet. 2023 Mar 11;401(10379):833-842
pubmed: 36930674
Emerg Infect Dis. 2022 Oct;28(10):1977-1981
pubmed: 35969420
Sci Rep. 2022 Dec 1;12(1):20763
pubmed: 36456577
Int J Environ Res Public Health. 2021 Aug 19;18(16):
pubmed: 34444497
Lancet Infect Dis. 2022 Jun;22(6):781-790
pubmed: 35366962